Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.04
-0.7%
$2.41
$1.87
▼
$8.21
$432.74M2.235.29 million shs4.87 million shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$29.08
+0.1%
$28.83
$5.21
▼
$30.39
$145.37M0.44112,909 shs712,400 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-0.49%-0.25%-15.21%-37.96%-43.94%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%0.00%0.00%0.00%+5.32%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.04
-0.7%
$2.41
$1.87
▼
$8.21
$432.74M2.235.29 million shs4.87 million shs
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$29.08
+0.1%
$28.83
$5.21
▼
$30.39
$145.37M0.44112,909 shs712,400 shs
Forget Nvidia, Meta, and Google. Here's The New Magnificent Seven. Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-0.49%-0.25%-15.21%-37.96%-43.94%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
0.00%0.00%0.00%0.00%+5.32%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
2.83
Moderate Buy$12.10494.59% Upside
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
1.00
SellN/AN/A

Current Analyst Ratings Breakdown

Latest MRSN and CTMX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
11/12/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Boost Price TargetOverweight$11.00 ➝ $12.00
11/6/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Boost Price TargetOutperform$11.00 ➝ $12.00
10/13/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Reiterated RatingOverweight
9/11/2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Reiterated RatingSell (D)
(Data available from 11/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$76.20M5.82N/AN/A$1.31 per share1.55
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
$33.18M4.38N/AN/A($1.92) per share-15.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$17.37M-$0.50N/AN/AN/A-608.98%-33.97%-27.19%N/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
-$69.19M-$13.88N/AN/AN/A-211.21%N/A-65.42%N/A

Latest MRSN and CTMX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
-$0.0719-$0.09-$0.0181-$0.09$10.38 million$1.69 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
7.82
7.82
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
N/A
1.39
1.39

Institutional Ownership

CompanyInstitutional Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
93.92%

Insider Ownership

CompanyInsider Ownership
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.80%
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
13.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
69218.01 million209.72 millionOptionable
Mersana Therapeutics, Inc. stock logo
MRSN
Mersana Therapeutics
1505.00 million4.35 millionOptionable

Recent News About These Companies

Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript
Mersana Therapeutics Earnings Preview

New MarketBeat Followers Over Time

Media Sentiment Over Time

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.04 -0.02 (-0.73%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$2.05 +0.01 (+0.74%)
As of 11/20/2026 07:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Mersana Therapeutics stock logo

Mersana Therapeutics NASDAQ:MRSN

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.